The immunosuppressant tacrolimus (TAC) is metabolized by both cytochrome P450 3A4
(CYP3A4) and CYP3A5 enzymes. It is common for European Americans (EA) to carry two …

Background. The CYP4503A5* 1 genotype is associated with lower tacrolimus
concentrations. Although its effect is important, it incompletely explains the variability in …

Tacrolimus is characterized by a highly variable pharmacokinetics (PK) and a small
therapeutic window. It is metabolized specifically by the CYP3A isoenzymes. This study …

The purpose of this study was to identify genotypes associated with dose-adjusted
tacrolimus trough concentrations (C0/D) in kidney transplant recipients using whole-exome …

Abstract Background Single nucleotide polymorphisms (SNPs) in the CYP3A5 and CYP3A4
genes have been reported to be an important cause of variability in the pharmacokinetics of …

Aim: Tacrolimus is a substrate of CYP3A4 and CYP3A5. The present study investigated the
impact of the CYP3A4* 1/* 1G polymorphism compared with CYP3A5 genotypes on the …

Tacrolimus is dependent on CYP3A5 enzyme for metabolism. Expression of the CYP3A5
enzyme is controlled by several alleles including CYP3A5* 1, CYP3A5* 3, CYP3A5* 6 and …

Tacrolimus (Tac) exhibits an interindividual pharmacokinetic variability that affects the dose
required to reach the target concentration in blood. Tac is metabolized by two enzymes of …

Objective Tacrolimus is used clinically for the long-term treatment of antirejection of
transplanted organs in liver and kidney transplant recipients, although dose optimization is …

Background: Tacrolimus (TAC), acting as a calcineurin inhibitor, is an immunosuppressant
widely used after kidney transplantation. TAC requires blood concentration monitoring due …